将无创肝脏评估整合入结肠镜筛查:前瞻性横断面研究
本研究前瞻性纳入≥50岁接受结肠镜筛查的成人,评估整合无创肝脏评估的可行性、接受度与检出率。610人入组(接受率88.2%),94.9%获得可靠肝硬度值;超声定义脂肪变55.5%,肝硬度≥1.50 m/s者占9.0%,风险因素标准仅捕获其中46/52例。
要点
- 结肠镜筛查人群整合肝脏弹性检测可行且接受度高(88.2%)。
- 超声脂肪变检出率55.5%,肝硬度≥1.50 m/s者占9.0%。
- 风险因素标准仅捕获46/52例肝硬度≥1.50 m/s者。
核心结论
- 将无创肝脏评估整合入结肠镜筛查就诊是可行且接受度高的,并识别出既往未诊断的脂肪变和肝硬度升高。
研究设计与样本
- 前瞻性横断面研究纳入≥50岁接受结肠镜筛查的成人,排除已知慢性肝病者,行肝脏超声和点剪切波弹性成像。
主要发现
- 692名受邀成人中610人入组(接受率88.2%),1例因失代偿性心衰排除;609人中578人(94.9%)获得可靠肝硬度测量。
- 超声定义脂肪变为55.5%;肝硬度超过1.30 m/s者占25.3%,≥1.50 m/s者占9.0%,≥1.70 m/s者占5.0%。
- 肝硬度≥1.50 m/s者中,代谢性暴露占63.5%,混合代谢-酒精性占21.2%,酒精相关占15.4%。
- 风险因素标准在76.6%参与者中满足,捕获46/52例肝硬度≥1.50 m/s者;FIB-4在该阈值下AUROC为0.682,敏感性从单阈值0.706降至年龄调整阈值0.529。
关键数值与推荐
- 肝硬度阈值预设为1.30、1.50、1.70 m/s(约5、7、9 kPa),分别对应不同风险分层。
- 肝硬度≥1.50 m/s视为显著纤维化,≥1.70 m/s视为代偿性晚期慢性肝病。
临床怎么用
- 在结肠镜筛查就诊时可考虑同步进行无创肝脏评估,以提高脂肪变和肝硬度升高的检出。
- 风险因素标准可能漏诊部分肝硬度升高者,FIB-4在该人群判别能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Steatotic liver disease is underdiagnosed despite guideline recommendations for risk-based case-finding. Colorectal cancer (CRC) screening colonoscopy engages a prevention-oriented, healthcare-seeking population in whom liver disease may go undetected. We assessed the feasibility, acceptance, and yield of non-invasive liver assessment integrated into screening colonoscopy visits. METHODS: This prospective cross-sectional study enrolled adults aged ≥50 years attending screening colonoscopy. Individuals with known chronic liver disease were excluded. Participants underwent hepatic ultrasound and point shear wave elastography. Liver stiffness measurements (LSM) were interpreted using prespecified thresholds of 1.30, 1.50, and 1.70 m/s (∼5, 7, and 9 kPa, respectively). We assessed whether risk-factor-based criteria would have identified participants with elevated stiffness, and evaluated the Fibrosis-4 index (FIB-4) against LSM thresholds. RESULTS: Of 692 adults offered participation, 610 enrolled (88.2% acceptance); one was excluded for decompensated heart failure. Reliable LSM was obtained in 578 of 609 (94.9%). Ultrasound-defined steatosis was identified in 55.5%. LSM exceeded 1.30 m/s in 25.3%; 9.0% and 5.0% met thresholds consistent with significant fibrosis (≥1.50 m/s) and compensated advanced chronic liver disease (≥1.70 m/s), respectively. Among participants with LSM ≥1.50 m/s, exposure profiles were metabolic in 63.5%, mixed metabolic-alcohol in 21.2%, and alcohol-related in 15.4%. Risk-factor criteria were met by 76.6% and captured 46/52 participants with LSM ≥1.50 m/s. At this threshold, FIB-4 showed modest discrimination (AUROC 0.682); sensitivity decreased from 0.706 using a single threshold to 0.529 using age-adjusted thresholds. DISCUSSION: Opportunistic liver assessment integrated into screening colonoscopy was feasible, well accepted, and identified previously undetected steatosis and elevated LSM.
引用
- Qasem M, Bednář O, Procházka V, et al. Integrating Non-Invasive Liver Assessment into Screening Colonoscopy: A Prospective Cross-Sectional Study. Am J Gastroenterol. 2026. PMID: 42895849. doi:10.14309/ajg.0000000000004236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。